It was reported the patient underwent implantation of an intracerebral ventrisculostomy (icv) set on (b)(6) 2019.On (b)(6) 2020, the patient initiated treatment with brineura (300 milligram, qow, icv).The most recent dose was administered on (b)(6) 2020.On (b)(6) 2020, before the infusion with brineura, the patient's cerebrospinal fluid (csf) cell count was measured and was normal with a value of 1 (units and reference range not reported).On (b)(6) 2020, the patient experienced fever and vomiting, and the number of csf cells increased to a value of 45, a grade 3 (pleocytosis), resulting in hospitalization.The investigator suspected bacterial meningitis and started administration of antibiotics (cefotaxime and vancomycin).On (b)(6) 2020, the fever disappeared and the number of csf cells decreased to a value of 11.In addition, a bacterial culture test was negative.Therefore, antibiotics were stopped on (b)(6) 2020.After that, the number of csf cells did not increase.No action was taken with brineura due to the event.The outcome of the event was reported as recovered/resolved on (b)(6) 2020.The investigator assessed the event of pleocytosis as related to treatment with brineura; therefore, this case qualifies for expedited reporting.The investigator assessed the event of pleocytosis as related to the icv device.According to the investigator, other etiological factors included the device or techniques.At the time of the event, the subject's vital signs were reported as: temperature (c): 38.9, respiratory rate (beath/min): 20, heart rate (bpm): 124, systolic blood pressure (mmhg): 108, diastolic blood pressure (mmhg): 75.And oxygen saturation (%): 98.On (b)(6) 2020, the patient had their icv device removed due to suspecteddevice-associated infection.
|